



IN THE CLAIMS:

Claim 1-6 (cancelled).

Claim 7 (currently amended): A compound of the formula B:



wherein:

X is O or H₂;

e is 0;

t is 1 to 4;

R^{2'}, R^{3'}, R^{4'}, and R^{5'} are independently selected from: H; C₁₋₈alkyl, alkenyl, alkynyl, aryl, heterocycle, -CO-NR^{6'}R^{7'} or -CO-OR^{6'}, unsubstituted or substituted with one or more of:

1) aryl or heterocycle, unsubstituted or substituted with:

a. C₁₋₄alkyl,

- b. $(CH_2)_iOR^{6'}$,
- c. $(CH_2)_iNR^{6'}R^{7'}$,
- d. halogen,

2) C_{3-6} cycloalkyl,

3) $OR^{6'}$,

4) $SR^{6'}, S(O)R^{6'}, SO_2R^{6'}$,

5) $-NR^{6'}R^{7'}$,

6) $-NR^{6'}-CO-R^{7'}$,

7) $-NR^{6'}-CO-NR^{7'}R^{8'}$,

8) $-O-CO-NR^{6'}R^{7'}$,

9) $-O-CO-OR^{6'}$,

10) $-O-NR^{6'}R^{7'}$,

11) $-SO_2NR^{6'}R^{7'}$,

12) $-NR^{6'}-SO_2-R^{7'}$,

13) $-CO-R^{6'}$, or

14) $-CO-OR^{6'}$;

and any two of $R^{2'}$, $R^{3'}$, $R^{4'}$, and $R^{5'}$ are optionally attached to the same carbon atom;

Y is aryl, heterocycle, unsubstituted or substituted with one or more of:

1) C_{1-4} alkyl, unsubstituted or substituted with:

- a. C_{1-4} alkoxy,
- b. $NR^{6'}R^{7'}$,
- c. C_{3-6} cycloalkyl,
- d. aryl or heterocycle,
- e. HO,

2) aryl or heterocycle,

3) halogen,

4) $OR^{6'}$,

5) $NR^{6'}R^{7'}$,

6) CN

7) NO_2 , or

8) CF₃;

R^{6'}, R^{7'} and R^{8'} are independently selected from: H; C₁₋₄alkyl, C₃₋₆cycloalkyl, heterocycle, aryl, aroyl, heteroaroyl, arylsulfonyl, heteroarylsulfonyl, unsubstituted or substituted with:

- a) C₁₋₄alkoxy,
- b) aryl or heterocycle,
- c) halogen,
- d) HO,
- e) -CO-R^{9'},
- f) -SO₂R^{9'}, wherein

R^{6'} and R^{7'} may be joined in a ring, and

R^{7'} and R^{8'} may be joined in a ring;

R^{9'} is C₁₋₄alkyl or aralkyl;


a pharmaceutically acceptable salt thereof.

Claim 8 (previously amended): The compound (2S)-2-(2-methoxy-ethyl)-1-((cis)-3-sulfanyl-pyrrolidin-2-ylmethyl)-4-naphthoyl-piperazine or a pharmaceutically acceptable salt thereof.

Claim 9 (currently amended): A pharmaceutical composition which comprises a compound according to ~~any one of claims 7 or 8~~ claim 7 or 8 and a pharmaceutically-acceptable carrier.

Claims 10-12 (cancelled).

Claim 13 (previously amended): A process for preparing compounds of the Formula B as defined in claim 7 which comprises deprotecting a compound of Formula VI:



wherein X^8 represents the right hand side of the Formula B as defined in claim 7, Pr^1 is H or an amino protecting group, Pr^2 is H or a thio protecting group and any functional groups in X^8 are optionally protected with the proviso that there is at least one protecting group and optionally, if desired, converting the product thus obtained into a pharmaceutically-acceptable salt thereof.

Claims 14-17 (cancelled).

Claim 18 (previously added): A method of treating a disease or medical condition mediated through farnesylation of CAAX-containing proteins which comprises administering to a warm-blooded animal an effective amount of a compound according to claim 7 or 8, wherein said disease or medical condition is carcinoma of the bladder, breast, colon, kidney, liver, lung, ovary, pancreas, stomach, cervix, thyroid or skin.

Claim 19 (previously added): A method of treating a disease or medical condition mediated through farnesylation of CAAX-containing proteins which comprises administering to a warm-blooded animal an effective amount of a compound according to claim 7 or 8, wherein said disease or medical condition is a hematopoietic tumor of lymphoid lineage selected from acute lymphocytic leukaemia, B-cell lymphoma and Burkitts lymphoma.

Claim 20 (previously added): A method of treating a disease or medical condition mediated through farnesylation of CAAX-containing proteins which comprises administering to a warm-blooded animal an effective amount of a compound according to claim 7 or 8,

wherein said disease or medical condition is a hematopoietic tumor of myeloid lineage selected from acute or chronic myelogenous leukemias and promyelocytic leukaemia.

Claim 21 (previously added): A method of treating a disease or medical condition mediated through farnesylation of CAAX-containing proteins which comprises administering to a warm-blooded animal an effective amount of a compound according to claim 7 or 8, wherein said disease or medical condition is a tumor of mesenchymal origin selected from fibrosarcoma and rhabdomyosarcoma.

Claim 22 (previously added): A method of treating a disease or medical condition mediated through farnesylation of CAAX-containing proteins which comprises administering to a warm-blooded animal an effective amount of a compound according to claim 7 or 8, wherein said disease or medical condition is a tumor selected from melanoma, seminoma, teratocarcinoma, neuroblastoma and glioma.